Cardiac Success Ltd. is an Israeli medical device medtech startup which is developing a transcatheter ventricular repair device for heart failure patient. Cardiac Success closed a $5.2 million Series A financing round led by 415 CAPITAL, a specialist VC firm that primarily backs innovative medical technology companies in the cardio-and neurovascular space.
In recent years Israel has become known as the startup state or Startup Nation. The country has had multi-billion dollar exits for numerous software and security companies. But Startup Nations is also known for its medtech startups. Israel has always been a center for medical research and innovation. Now put that together with its startup culture and you have medtech nation.
And there seems to be an explosion of medtech startups coming out of Israel these days. Israeli startup Laguna Health is a post-hospital recovery assurance medtech company offering a value-based solution to reduce costly readmissions and shorten recovery times. Lydus Medical is an Israeli medtech startup developing a novel product line for automating the creation of small blood vessel anastomoses. The company’s Vesseal is an automated microvascular suturing device that delivers a standardized, thread-only, omni-vessel anastomosis to enable simple, fast, safe, and effective procedures.
Another Israeli medtech startup which deals with heart treatments is VESSL Therapeutics. VESSL develops new treatments for a wide range of blood-vessel-related disorders. Founded in 2000 by CEO Prof. Moshe Flugelman and formerly called MGVS, VESSL Therapeutics develops cell-based therapies for patients who suffer from cardiovascular and other vascular-related conditions and cannot be treated adequately with existing therapeutic modalities. Its core technology is based on an integrative approach for the treatment of cardiovascular disease.
So what does Cardiac Success offer?
Founded in 2017 in the Alon Medtech Ventures’ incubator by the serial entrepreneur Dr. Shimon Eckhouse and Dr. David Neustadter, Cardiac Success is developing the V-sling device. The company states that this will improve the lives of the millions of patients who suffer and deteriorate from Heart Failure with Reduced Ejection Fraction (HFrEF). The V-sling is a transcatheter ventricular repair device designed based on a successful surgical papillary muscle approximation procedure.
The Mayo Clinic explains that a Transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis). Transcatheter aortic valve replacement is sometimes called transcatheter aortic valve implantation (TAVI).
Cardiac Success says that the “V-sling” system is a “safe anchorless implant” to treat left ventricular dysfunction, where the left ventricle is not able to pump enough blood out of the heart leading to reduced ejection fraction and low cardiac output. The “V-sling” treats the problem directly at its source by repositioning the papillary muscles and restoring the conical shape of the left ventricle for improved cardiac function.
Boaz Manash, CEO of Cardiac Success, said, “There are millions of patients who, despite guidance-directed medical therapy, continue to suffer and deteriorate from Heart Failure with Reduced Ejection Fraction (HFrEF).”
Mr. Manash added, “This new funding from experienced investors and strategic partners in the cardiac field, shows their confidence in the “V-sling” system and will enable us to accelerate our clinical development to provide a treatment option for these heart failure patients.”